Informa Life Sciences will be holding its 24th Annual EU Pharmaceutical Law Forum on May 19-21, 2015 in Brussels, Belgium. The conference will offer presentations on the following topics:
• Feedback from the EU Commission on competition law (keynote presentation) -- to be presented by a representative from DG Competition, European Commission;
• Reverse payment patent settlements;
• Examining recent EU merger control cases in the pharmaceutical industry;
• Assessing pricing: Discounts and rebates;
• Review of high profile national cases/decisions in competition law;
• Unified Patent Court: Feedback from the European Commission (keynote presentation) -- to be presented by Michael Koenig, Deputy Head of Unit, European Commission;
• Unified Patent Court: Feedback from private practice;
• Cross-border relief for patent infringement – should the practice be encouraged? Lessons learned from pemetrexed;
• Understanding European patent litigation and SPC's;
• Lifecycle management with respect to IP, competition law and regulatory frameworks;
• Second medical use claims (evening seminar);
• 2015 - 50 years of EU pharmaceutical legislation -- an area where law does not stand still;
• Transparency of clinical trial data, regulatory data and prices plus a review of the clinical trials regulation;
• Pricing and reimbursement and market access in the EU: Pharmaceutical and medical devices;
• The EU Data Protection Regulation -- Where do we stand?
• Update on IP regulatory rights: What’s new?
• Examining unlicensed use and off-label use;
• Adaptive licensing and early access to medicines;
• Transparency with regard to the relationship with healthcare professionals;
• Innovative stakeholder (customer and patients) engagement;
• Feedback from the EU Commission on the EU regulatory framework for medical devices (keynote presentation) -- to be presented by Erik Hansson, Deputy Head of Unit, EU Commission;
• IVDs and revisions to the regulation;
• Biosimilars and the regulatory frameworks (evening seminar);
• Detailing effective negotiation strategies;
• Examining commercial intellectual property issues in collaboration and licensing agreements;
• The importance of due diligence;
• Obligations to exploit;
• Assessing the financial aspects of licensing and collaboration agreements;
• Dealing contractually with 3rd party IP rights;
• The European Unified Patent from a transactional and property perspective;
• Structuring the alliance management in licensing deals: A legal and commercial perspective;
• Negotiating and drafting termination provisions; and
• Asset centric corporate structures (evening seminar).
A complete brochure for this conference, including an agenda, detailed descriptions of conference sessions, list of speakers, and registration form can be obtained here.
Registration fee packages for the forum can be found here. Those interested in registering for the conference can do so here, by e-mailing [email protected], by calling +44(0) 20 7017 7481, or by faxing a registration form to +44(0) 20 7017 7823.
Patent Docs is a media partner of the EU Pharmaceutical Law Forum.
Comments